Entia Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ERGO research report →
Companywww.entiabio.com
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products.
- CEO
- Timothy A. Timmins
- IPO
- 2008
- Employees
- 6
- HQ
- Sherwood, OR, US
Price Chart
Valuation
- Market Cap
- $20.20K
- P/E
- -0.01
- P/S
- 0.08
- P/B
- -0.01
- EV/EBITDA
- -0.76
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 65.53%
- Op Margin
- -439.75%
- Net Margin
- -554.75%
- ROE
- 106.80%
- ROIC
- 126.81%
Growth & Income
- Revenue
- $265.47K · -23.48%
- Net Income
- $-1,472,664 · 38.88%
- EPS
- $-0.05 · 47.28%
- Op Income
- $-1,167,379
- FCF YoY
- -29.46%
Performance & Tape
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 38.17
- Avg Volume
- 290
Get TickerSpark's AI analysis on ERGO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 16, 17 | HAUSMAN MARVIN S MD | other | 250,000 |
| Feb 14, 17 | HAUSMAN MARVIN S MD | other | 300,000 |
| Feb 14, 17 | HAUSMAN MARVIN S MD | other | 200,000 |
| Feb 14, 17 | HAUSMAN MARVIN S MD | other | 600,000 |
| Feb 14, 17 | HAUSMAN MARVIN S MD | other | 1,861,170 |
| Feb 16, 17 | JOHNSON CARL J | other | 250,000 |
| Feb 14, 17 | JOHNSON CARL J | other | 300,000 |
| Feb 14, 17 | JOHNSON CARL J | other | 300,000 |
| Dec 5, 16 | HAUSMAN MARVIN S MD | buy | 40,000 |
| Dec 5, 16 | HAUSMAN MARVIN S MD | buy | 0 |
Our ERGO Coverage
We haven't published any research on ERGO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ERGO Report →